M&A / Deals Eli Lilly to buy trio of vaccine developers in $3.8bn outlay Pharmaceutical TechnologyVia the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.Infectious DiseaseRead full story pharminent May 26, 2026 (Last updated: May 26, 2026) Pharmaceutical Technology Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Arthrosi drug trial in gout delivers for new owner SobiNext: Early data for heart drug affirm Lilly’s billion-dollar bet on Verve Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
